NASDAQ
05.06.26 | 21:59
1,535 US-Dollar
-0,32 % -0,005
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 14.05. | Earnings Call: ALX Oncology übertrifft Gewinnprognose für Q1 2026 | 1 | Investing.com Deutsch | ||
| 09.05. | Alx Oncology outlines interim ASPEN-09 data from ~80 patients by mid-2027 as CD47-high cohort shows 22-month median PFS | 1 | Seeking Alpha | ||
| 08.05. | ALX Oncology: 100 % Ansprechrate in Studie bestätigt CD47-Strategie | 6 | Investing.com Deutsch | ||
| 08.05. | ALX Oncology Q1 2026 slides: 100% response validates CD47 strategy | 3 | Investing.com | ||
| 08.05. | ALX Oncology GAAP EPS of -$0.17 beats by $0.02 | 1 | Seeking Alpha | ||
| 08.05. | ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update | 625 | GlobeNewswire (Europe) | - Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable... ► Artikel lesen | |
| 08.05. | ALX ONCOLOGY HOLDINGS INC - 10-Q, Quarterly Report | - | SEC Filings | ||
| 08.05. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | - | SEC Filings | ||
| ALX ONCOLOGY Aktie jetzt für 0€ handeln | |||||
| 07.05. | ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression | 226 | GlobeNewswire (Europe) | - Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept - - Findings are consistent with previous results from the... ► Artikel lesen | |
| 17.04. | ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules | 2 | GlobeNewswire (USA) | ||
| 13.04. | ALX Oncology names Jeff Knight as chief development officer | 1 | Investing.com | ||
| 13.04. | ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer | 243 | GlobeNewswire (Europe) | - Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution SOUTH SAN FRANCISCO, Calif., April 13... ► Artikel lesen | |
| 13.04. | ALX ONCOLOGY HOLDINGS INC - 8-K, Current Report | - | SEC Filings | ||
| 19.03. | Wells Fargo initiates ALX Oncology stock with overweight rating | 6 | Investing.com | ||
| 10.03. | Rüstungs-Rallye nach Iran-Angriff: Rheinmetall, Palantir, DroneShield und Harvest Technology im Fokus der Anleger | Small- & Micro Cap Investment | |||
| 09.03. | ALX ONCOLOGY HOLDINGS INC - 10-K, Annual Report | 1 | SEC Filings | ||
| 28.02. | ALX Oncology outlines pivotal trial readiness by end of 2026 with expanded ASPEN-09 study and $150M financing | 1 | Seeking Alpha | ||
| 27.02. | ALX Oncology: Aktie fällt nach verfehlter Gewinnprognose für Q4 2025 | 2 | Investing.com Deutsch | ||
| 27.02. | ALX Oncology GAAP EPS of -$0.42 misses by $0.06 | 1 | Seeking Alpha | ||
| 27.02. | ALX Oncology Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update | 1.472 | GlobeNewswire (Europe) | - Clinical development for both the investigational CD47-inhibitor evorpacept and the novel EGFR-targeted antibody-drug conjugate ALX2004 remains on track following strong 2025 execution; company... ► Artikel lesen |
1 2 Weiter >>
39 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| EVOTEC | 4,932 | -3,58 % | EQS-News: Evotec SE: Evotec ernennt Rui Wang zum Head of Global In Silico & AI | EQS-News: Evotec SE
/ Schlagwort(e): Sonstiges
Evotec ernennt Rui Wang zum Head of Global In Silico & AI
02.06.2026 / 07:30 CET/CEST
Für den Inhalt der Mitteilung ist... ► Artikel lesen | |
| MODERNA | 41,190 | +0,12 % | Opening Bell: Bitcoin, Strategy, Broadcom, Marvell, Micron, Axon Enterprise, Moderna, Lululemon | Die US-Börsen haben am Donnerstag eine zweigeteilte Entwicklung gezeigt. Der Dow Jones eröffnete mit klaren Gewinnen, baute diese im Verlauf deutlich aus und schloss 1,73 Prozent fester. Der Nasdaq... ► Artikel lesen | |
| NOVAVAX | 8,080 | -1,70 % | NOVAVAX INC: Stabilität vor der nächsten Bewegung | ||
| CRISPR THERAPEUTICS | 44,705 | -0,60 % | CRISPR Therapeutics AG (CRSP): One of The most Shorted Mid Cap Stocks to Buy on Robust Gene Editing Pipeline | ||
| INOVIO PHARMACEUTICALS | 0,932 | +0,87 % | H.C. Wainwright senkt Kursziel für Inovio wegen höherer Aktienanzahl | ||
| INTELLIA THERAPEUTICS | 11,240 | -4,26 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| DEFENCE THERAPEUTICS | 0,328 | -2,38 % | Defence Therapeutics Inc.: Defence Therapeutics Appoints Seasoned Biopharmaceutical Executive Dr John Beaver to Its Board of Directors | Montreal, Quebec--(Newsfile Corp. - June 3, 2026) - Defence Therapeutics Inc. (CSE: DTC) (OTCQB: DTCFF) (FSE: DTC) ("Defence" or the "Company"), a publicly traded biotechnology and precision intracellular... ► Artikel lesen | |
| EDITAS MEDICINE | 2,340 | -0,43 % | Editas Medicine, Inc.: Editas Medicine Reports New Preclinical Data Demonstrating Progress of EDIT-401 as Potential Treatment for Hyperlipidemia at the American Society of Gene and Cell Therapy 2026 Annual Meeting | CAMBRIDGE, Mass., May 14, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, shared new preclinical... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 49,500 | +0,49 % | BIOMARIN PHARMACEUTICAL INC - 8-K, Current Report | ||
| EXELIXIS | 45,530 | -0,40 % | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 13,800 | +0,88 % | Improving Profitability Supports Sarepta Therapeutics Inc. (SRPT) as One of the Most Shorted Small-Cap Stocks to Buy | ||
| HALOZYME THERAPEUTICS | 61,62 | -0,71 % | Benchmark reiterates Halozyme stock Buy rating on long-term potential | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,235 | -1,56 % | PACIFIC BIOSCIENCES OF CALIFORNIA, INC. - 8-K, Current Report | ||
| NEUROCRINE BIOSCIENCES | 141,85 | 0,00 % | Neurocrine to present two-year Crenessity data at ENDO 2026 | ||
| VAXART | 0,380 | 0,00 % | Vaxart, Inc.: Vaxart Files Definitive Proxy Statement and Mails Letter to Shareholders | Emphasizes Importance of Experienced Biotech Leadership as Vaxart Advances Clinical and Strategic Priorities with Multiple Value-Creating Milestones Ahead Highlights Significant Risk of Replacing... ► Artikel lesen |
ALX ONCOLOGY HOLDINGS INC gehört der Branche Biotechnologie an. Die relative Kursveränderung beträgt aktuell -0,32 % bei einem Aktienkurs von 1,535 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALX ONCOLOGY HOLDINGS INC finden Sie auf Wallstreet Online.